Biogen Idec Inc (BIIB) 278.85 $BIIB
Perrigo Beats on Q3 Earnings, Misses Revenues, Cuts Jobs
Zacks Equity Research - Zacks Investment Research - 1 hr 20 mins ago
Perrigo Company's (PRGO) third-quarter 2015 earnings of $1.76 per share beat the Zacks Consensus Estimate.
BIIB: 278.85 (+2.51), PRGO: 146.61 (-8.63), MYL: 38.83 (-2.06), TEVA: 56.09 (-1.83)
No Easy Cure for What Ails Biotech Stocks
at The Street - 1 hr 24 mins ago
Meanwhile, make incremental moves until the onslaught in the space is over.
BIIB: 278.85 (+2.51), VRX: 102.45 (-16.16), GILD: 102.42 (+0.69), MYL: 38.83 (-2.06), AMGN: 152.29 (+2.20)
Global Hemophilia A Market 2015-2019
M2 - 2 hrs 36 mins ago
Research and Markets (http://www.researchandmarkets.com/research/kmq3vn/global_hemophilia) has announced the addition of the "Global Hemophilia A Market 2015-2019" report to their offering. The global hemophilia A drugs market to grow at a CAGR of 6.25% over the period 2014-2019. The report, Global Hemophilia A Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers APAC, Europe, and Americas; it also covers the landscape of the global hemophilia A drugs market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market. The report covers the current scenario and the growth prospects of the global hemophilia A drugs market for the period of 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various drugs used in the treatment and prevention of hemophilia A. In this report, the market is also segmented based on the type of therapy. There are new technological advancements in terms of drug manufacturing, development, and delivery. These advances has led to the development of recombinant products. For instance, animal or human plasma proteins are not used to manufacture NovoSeven, thereby decreasing the risk of infection. The use of Fc-fusion technology has increased the half-life of Eloctate in blood, thereby improving drug action. According to the report, the development of new hemophilia A therapeutics with prolonged action is prompting market growth. Vendors are developing a number of products, which are in the pipeline stage. The anticipated approval of these products will impact the growth of the market during the forecast period. Further, the report states that the high cost of treatment leads to the discontinuation of therapy, thereby hampering market growth. Key vendors - Baxter International - Bayer's - CSL Behring - Novo Nordisk - Pfizer Other prominent vendors - Alnylam Pharmaceuticals - Amarna Therapeutics - Asklepios - Biogen Idec - Catalyst Biosciences - Dimension Therapeutics - Dong-A Socio - Emergent BioSolutions - Grifols - Inspiration Biopharmaceuticals - Kedrion Biopharma - Octapharma - OPKO Health - rEVO Biologics - Sangamo BioSciences - Spark Therapeutics - UniQure For more information visit http://www.researchandmarkets.com/research/km...hemophilia
BIIB: 278.85 (+2.51), NVO: 53.49 (-0.92), EBS: 30.54 (-0.13), OPK: 9.04 (-0.11), ONCE: 57.98 (+2.04), BAX: 34.89 (-0.71), SGMO: 6.39 (-0.03), CBIO: 4.44 (+0.47), RBIO: (), DMTX: 11.50 (-1.10)
Biogen Idec (BIIB) Earnings Report: Q3 2015 Conference Call Transcript
at The Street - Wed Oct 21, 8:41PM CDT
The following Biogen Idec (BIIB) conference call took place on October 21, 2015, 08:30 AM ET. This is a transcript of that earnings call:
BIIB: 278.85 (+2.51)
Biogen tops Q3, will cut jobs
at Investor's Business Daily - Wed Oct 21, 5:49PM CDT
The struggling biotech announced an 11% workforce reduction and the discontinuation of some clinical programs. Those savings, in part, prompted Biogen (BIIB) to raise full-year EPS guidance by more than 70 cents to $16.20-$16.50. It also lifted...
BIIB: 278.85 (+2.51)
Watch for Biogen Idec to Potentially Pullback After Gaining 3.96% Yesterday
Comtex SmarTrend(R) - Wed Oct 21, 3:42PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $262.45 to a high of $291.01. Yesterday, the shares gained 4.0%, which took the trading range above the 3-day high of $277.29 on volume of 8.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BIIB: 278.85 (+2.51)
Look for Shares of Biogen Idec to Potentially Pullback after Yesterday's 3.96% Rise
Comtex SmarTrend(R) - Wed Oct 21, 3:42PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $262.45 to a high of $291.01. Yesterday, the shares gained 4.0%, which took the trading range above the 3-day high of $277.29 on volume of 8.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BIIB: 278.85 (+2.51)
Stocks Fall; Valeant Defends Accounting Practices
at The Street - Wed Oct 21, 2:02PM CDT
Stocks relinquish gains made earlier Wednesday as a selloff in Valeant Pharmaceuticals pressures the rest of the biotech sector.
TSLA: 214.76 (+4.67), BIIB: 278.85 (+2.51), F: 15.61 (+0.20), VRX: 102.69 (-15.92), KMB: 121.00 (+2.91), IBB: 305.37 (+0.91), TM: 125.43 (+1.73), SBUX: 61.22 (+0.69), YHOO: 31.85 (+0.73), CMG: 660.10 (-5.57), ABBV: 53.56 (-0.27), GOOGL: 682.32 (+10.52), HMC: 33.06 (+0.36), AAPL: 115.10 (+1.34), KO: 43.64 (+1.45), AMZN: 566.90 (+11.13), MU: 16.70 (+0.27), PFE: 33.13 (-0.33), LLY: 76.73 (-0.28), FCAU: 15.28 (+0.08), BMY: 63.04 (+0.53), BA: 146.86 (+5.67), WDC: 72.40 (+0.96), LRCX: 72.26 (+1.47), MCD: 110.27 (+7.73), GM: 35.47 (+0.05), KLAC: 64.96 (+0.98), RACE: 56.31 (+1.31), SNDK: 76.90 (+0.12)
Biogen Banks on High-Risk Drugs to Recapture Biotech Buzz
at The Street - Wed Oct 21, 12:46PM CDT
Biotech is a high-growth industry fueled by scientific innovation. The snapshot of Biogen Wednesday lacks the biotech buzz for which investors are willing to pay a premium.
BIIB: 278.85 (+2.51)
Biogen cutting 11 percent of its workforce
AP - Wed Oct 21, 12:39PM CDT
NEW YORK (AP) — Biogen plans to cut about 11 percent of its workforce as it refocuses its research on treatments for Alzheimer's disease and multiple sclerosis.
BIIB: 278.85 (+2.51)
Downtrend Call Working As Biogen Idec Stock Falls 8.2% (BIIB)
Comtex SmarTrend(R) - Wed Oct 21, 12:15PM CDT
SmarTrend identified a Downtrend for Biogen Idec (NASDAQ:BIIB) on September 25th, 2015 at $289.55. In approximately 4 weeks, Biogen Idec has returned 8.24% as of today's recent price of $265.68.
BIIB: 278.85 (+2.51)
Biogen To Cut 11% of Its Workforce As Part Of Restructuring Plan
Madeleine Johnson - Zacks Investment Research - Wed Oct 21, 11:31AM CDT
The biotech giant is also ending many of its drug development programs along with the workforce reduction.
WFM: 32.92 (-0.06), BIIB: 278.85 (+2.51), WMT: 58.95 (+0.31), TWTR: 29.50 (+0.20), HPQ: 28.89 (+0.66)
Here's Why Biogen (BIIB) Stock Is Climbing Today
at The Street - Wed Oct 21, 11:15AM CDT
Biogen (BIIB) stock is gaining in early afternoon trading on Wednesday, after reporting job cuts totaling 11% of its workforce and third quarter earnings results.
BIIB: 278.85 (+2.51)
Biogen Tops Q3 Earnings, Announces Job Cuts, Ups View
Arpita Dutt - Zacks Investment Research - Wed Oct 21, 10:40AM CDT
Biogen (BIIB) surpassed Q3 earnings expectations by a wide margin.
BIIB: 278.85 (+2.51), AMGN: 152.29 (+2.20), AEGR: 15.39 (+0.41)
Biogen Beats Q3 Views, Cuts Workforce, Lifts Guidance
at Investor's Business Daily - Wed Oct 21, 9:50AM CDT
Beleaguered big biotech Biogen (BIIB) beat Q3 estimates and raised guidance Wednesday morning while announcing a round of layoffs and the failure of a multiple-sclerosis drug trial. Biogen stock rose as much as 9.5% in early trading. Biogen made...
BIIB: 278.85 (+2.51)
Early Gains Fizzle, Turn Mixed; Biogen, Ferrari Rise
at Investor's Business Daily - Wed Oct 21, 9:47AM CDT
Leading indexes turned Wednesday's modest opening gains to mixed and busy action, powered primarily by quarterly reports and company news. The Nasdaq backed out of a narrow advance and slipped 0.2%. The Dow Jones industrial average and the S&P 500...
BIIB: 278.85 (+2.51), MU: 16.70 (+0.27), NTES: 139.15 (+1.98), HA: 33.62 (+0.75), DIS: 112.72 (+2.63), MANH: 71.32 (+1.24), WDC: 72.40 (+0.96), BA: 146.86 (+5.67), AOS: 72.46 (+3.79), OZRK: 48.78 (+0.91), LRCX: 72.26 (+1.47), CMG: 660.10 (-5.57), CRUS: 32.41 (-0.48), KLAC: 64.96 (+0.98), RACE: 56.31 (+1.31), SNDK: 76.90 (+0.12)
Stocks Turn Lower as Valeant Dents Biotech Sector
at The Street - Wed Oct 21, 9:41AM CDT
Stocks turn lower by mid-morning Wednesday as plummeting Valeant Pharmaceuticals shares pull the biotech sector to the downside.
BIIB: 278.85 (+2.51), TSLA: 214.76 (+4.67), VRX: 102.53 (-16.08), KMB: 121.00 (+2.91), IBB: 305.37 (+0.91), SBUX: 61.22 (+0.69), YHOO: 31.85 (+0.73), CMG: 660.10 (-5.57), ABBV: 53.56 (-0.27), GOOGL: 682.32 (+10.52), AAPL: 115.10 (+1.34), KO: 43.64 (+1.45), AMZN: 566.90 (+11.13), MU: 16.70 (+0.27), PFE: 33.13 (-0.33), FCAU: 15.28 (+0.08), BA: 146.86 (+5.67), WDC: 72.40 (+0.96), CELG: 116.56 (+0.64), GILD: 102.42 (+0.69), LRCX: 72.26 (+1.47), GM: 35.47 (+0.05), MCD: 110.27 (+7.73), KLAC: 64.96 (+0.98), RACE: 56.31 (+1.31), SNDK: 76.90 (+0.12)
Stock Market News for October 21, 2015
Zacks Equity Research - Zacks Investment Research - Wed Oct 21, 9:10AM CDT
Benchmarks ended in the red on Tuesday, dragged down by declines in biotech and healthcare stocks
BIIB: 278.85 (+2.51), HOG: 47.64 (+0.61), IBM: 144.55 (+3.63), GILD: 102.42 (+0.69), UTX: 99.81 (+1.84), PFE: 33.13 (-0.33), MRK: 50.89 (+0.30), AMGN: 152.29 (+2.20), VZ: 45.81 (+0.95), REGN: 523.80 (+5.27), TRV: 112.39 (+1.69), CELG: 116.56 (+0.64)
Biogen (BIIB) Beats on 3Q Earnings & Revenues
Zacks Equity Research - Zacks Investment Research - Wed Oct 21, 7:54AM CDT
Biogen's (BIIB) third quarter results were well above expectations with revenues also topping estimates.
BIIB: 278.85 (+2.51)
Stock Futures Rise as Boeing, GM Beat Profit Forecasts
at The Street - Wed Oct 21, 7:25AM CDT
Stock futures are higher on Wednesday after better-than-expected earnings from General Motors and Boeing.
KO: 43.64 (+1.45), AMZN: 566.90 (+11.13), BIIB: 278.85 (+2.51), TSLA: 214.76 (+4.67), KMB: 121.00 (+2.91), FCAU: 15.28 (+0.08), BA: 146.86 (+5.67), SBUX: 61.22 (+0.69), YHOO: 31.85 (+0.73), CMG: 660.10 (-5.57), GM: 35.47 (+0.05), MCD: 110.27 (+7.73), GOOGL: 682.32 (+10.52), AAPL: 115.10 (+1.34)
Perrigo Beats on Q3 Earnings, Misses Revenues, Cuts Jobs
Zacks Equity Research - Zacks Investment Research - 1 hr 20 mins ago
Perrigo Company's (PRGO) third-quarter 2015 earnings of $1.76 per share beat the Zacks Consensus Estimate.
BIIB: 278.85 (+2.51), PRGO: 146.61 (-8.63), MYL: 38.83 (-2.06), TEVA: 56.09 (-1.83)
No Easy Cure for What Ails Biotech Stocks
at The Street - 1 hr 24 mins ago
Meanwhile, make incremental moves until the onslaught in the space is over.
BIIB: 278.85 (+2.51), VRX: 102.45 (-16.16), GILD: 102.42 (+0.69), MYL: 38.83 (-2.06), AMGN: 152.29 (+2.20)
Global Hemophilia A Market 2015-2019
M2 - 2 hrs 36 mins ago
Research and Markets (http://www.researchandmarkets.com/research/kmq3vn/global_hemophilia) has announced the addition of the "Global Hemophilia A Market 2015-2019" report to their offering. The global hemophilia A drugs market to grow at a CAGR of 6.25% over the period 2014-2019. The report, Global Hemophilia A Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers APAC, Europe, and Americas; it also covers the landscape of the global hemophilia A drugs market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market. The report covers the current scenario and the growth prospects of the global hemophilia A drugs market for the period of 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various drugs used in the treatment and prevention of hemophilia A. In this report, the market is also segmented based on the type of therapy. There are new technological advancements in terms of drug manufacturing, development, and delivery. These advances has led to the development of recombinant products. For instance, animal or human plasma proteins are not used to manufacture NovoSeven, thereby decreasing the risk of infection. The use of Fc-fusion technology has increased the half-life of Eloctate in blood, thereby improving drug action. According to the report, the development of new hemophilia A therapeutics with prolonged action is prompting market growth. Vendors are developing a number of products, which are in the pipeline stage. The anticipated approval of these products will impact the growth of the market during the forecast period. Further, the report states that the high cost of treatment leads to the discontinuation of therapy, thereby hampering market growth. Key vendors - Baxter International - Bayer's - CSL Behring - Novo Nordisk - Pfizer Other prominent vendors - Alnylam Pharmaceuticals - Amarna Therapeutics - Asklepios - Biogen Idec - Catalyst Biosciences - Dimension Therapeutics - Dong-A Socio - Emergent BioSolutions - Grifols - Inspiration Biopharmaceuticals - Kedrion Biopharma - Octapharma - OPKO Health - rEVO Biologics - Sangamo BioSciences - Spark Therapeutics - UniQure For more information visit http://www.researchandmarkets.com/research/km...hemophilia
BIIB: 278.85 (+2.51), NVO: 53.49 (-0.92), EBS: 30.54 (-0.13), OPK: 9.04 (-0.11), ONCE: 57.98 (+2.04), BAX: 34.89 (-0.71), SGMO: 6.39 (-0.03), CBIO: 4.44 (+0.47), RBIO: (), DMTX: 11.50 (-1.10)
Biogen Idec (BIIB) Earnings Report: Q3 2015 Conference Call Transcript
at The Street - Wed Oct 21, 8:41PM CDT
The following Biogen Idec (BIIB) conference call took place on October 21, 2015, 08:30 AM ET. This is a transcript of that earnings call:
BIIB: 278.85 (+2.51)
Biogen tops Q3, will cut jobs
at Investor's Business Daily - Wed Oct 21, 5:49PM CDT
The struggling biotech announced an 11% workforce reduction and the discontinuation of some clinical programs. Those savings, in part, prompted Biogen (BIIB) to raise full-year EPS guidance by more than 70 cents to $16.20-$16.50. It also lifted...
BIIB: 278.85 (+2.51)
Watch for Biogen Idec to Potentially Pullback After Gaining 3.96% Yesterday
Comtex SmarTrend(R) - Wed Oct 21, 3:42PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $262.45 to a high of $291.01. Yesterday, the shares gained 4.0%, which took the trading range above the 3-day high of $277.29 on volume of 8.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BIIB: 278.85 (+2.51)
Look for Shares of Biogen Idec to Potentially Pullback after Yesterday's 3.96% Rise
Comtex SmarTrend(R) - Wed Oct 21, 3:42PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $262.45 to a high of $291.01. Yesterday, the shares gained 4.0%, which took the trading range above the 3-day high of $277.29 on volume of 8.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BIIB: 278.85 (+2.51)
Stocks Fall; Valeant Defends Accounting Practices
at The Street - Wed Oct 21, 2:02PM CDT
Stocks relinquish gains made earlier Wednesday as a selloff in Valeant Pharmaceuticals pressures the rest of the biotech sector.
TSLA: 214.76 (+4.67), BIIB: 278.85 (+2.51), F: 15.61 (+0.20), VRX: 102.69 (-15.92), KMB: 121.00 (+2.91), IBB: 305.37 (+0.91), TM: 125.43 (+1.73), SBUX: 61.22 (+0.69), YHOO: 31.85 (+0.73), CMG: 660.10 (-5.57), ABBV: 53.56 (-0.27), GOOGL: 682.32 (+10.52), HMC: 33.06 (+0.36), AAPL: 115.10 (+1.34), KO: 43.64 (+1.45), AMZN: 566.90 (+11.13), MU: 16.70 (+0.27), PFE: 33.13 (-0.33), LLY: 76.73 (-0.28), FCAU: 15.28 (+0.08), BMY: 63.04 (+0.53), BA: 146.86 (+5.67), WDC: 72.40 (+0.96), LRCX: 72.26 (+1.47), MCD: 110.27 (+7.73), GM: 35.47 (+0.05), KLAC: 64.96 (+0.98), RACE: 56.31 (+1.31), SNDK: 76.90 (+0.12)
Biogen Banks on High-Risk Drugs to Recapture Biotech Buzz
at The Street - Wed Oct 21, 12:46PM CDT
Biotech is a high-growth industry fueled by scientific innovation. The snapshot of Biogen Wednesday lacks the biotech buzz for which investors are willing to pay a premium.
BIIB: 278.85 (+2.51)
Biogen cutting 11 percent of its workforce
AP - Wed Oct 21, 12:39PM CDT
NEW YORK (AP) — Biogen plans to cut about 11 percent of its workforce as it refocuses its research on treatments for Alzheimer's disease and multiple sclerosis.
BIIB: 278.85 (+2.51)
Downtrend Call Working As Biogen Idec Stock Falls 8.2% (BIIB)
Comtex SmarTrend(R) - Wed Oct 21, 12:15PM CDT
SmarTrend identified a Downtrend for Biogen Idec (NASDAQ:BIIB) on September 25th, 2015 at $289.55. In approximately 4 weeks, Biogen Idec has returned 8.24% as of today's recent price of $265.68.
BIIB: 278.85 (+2.51)
Biogen To Cut 11% of Its Workforce As Part Of Restructuring Plan
Madeleine Johnson - Zacks Investment Research - Wed Oct 21, 11:31AM CDT
The biotech giant is also ending many of its drug development programs along with the workforce reduction.
WFM: 32.92 (-0.06), BIIB: 278.85 (+2.51), WMT: 58.95 (+0.31), TWTR: 29.50 (+0.20), HPQ: 28.89 (+0.66)
Here's Why Biogen (BIIB) Stock Is Climbing Today
at The Street - Wed Oct 21, 11:15AM CDT
Biogen (BIIB) stock is gaining in early afternoon trading on Wednesday, after reporting job cuts totaling 11% of its workforce and third quarter earnings results.
BIIB: 278.85 (+2.51)
Biogen Tops Q3 Earnings, Announces Job Cuts, Ups View
Arpita Dutt - Zacks Investment Research - Wed Oct 21, 10:40AM CDT
Biogen (BIIB) surpassed Q3 earnings expectations by a wide margin.
BIIB: 278.85 (+2.51), AMGN: 152.29 (+2.20), AEGR: 15.39 (+0.41)
Biogen Beats Q3 Views, Cuts Workforce, Lifts Guidance
at Investor's Business Daily - Wed Oct 21, 9:50AM CDT
Beleaguered big biotech Biogen (BIIB) beat Q3 estimates and raised guidance Wednesday morning while announcing a round of layoffs and the failure of a multiple-sclerosis drug trial. Biogen stock rose as much as 9.5% in early trading. Biogen made...
BIIB: 278.85 (+2.51)
Early Gains Fizzle, Turn Mixed; Biogen, Ferrari Rise
at Investor's Business Daily - Wed Oct 21, 9:47AM CDT
Leading indexes turned Wednesday's modest opening gains to mixed and busy action, powered primarily by quarterly reports and company news. The Nasdaq backed out of a narrow advance and slipped 0.2%. The Dow Jones industrial average and the S&P 500...
BIIB: 278.85 (+2.51), MU: 16.70 (+0.27), NTES: 139.15 (+1.98), HA: 33.62 (+0.75), DIS: 112.72 (+2.63), MANH: 71.32 (+1.24), WDC: 72.40 (+0.96), BA: 146.86 (+5.67), AOS: 72.46 (+3.79), OZRK: 48.78 (+0.91), LRCX: 72.26 (+1.47), CMG: 660.10 (-5.57), CRUS: 32.41 (-0.48), KLAC: 64.96 (+0.98), RACE: 56.31 (+1.31), SNDK: 76.90 (+0.12)
Stocks Turn Lower as Valeant Dents Biotech Sector
at The Street - Wed Oct 21, 9:41AM CDT
Stocks turn lower by mid-morning Wednesday as plummeting Valeant Pharmaceuticals shares pull the biotech sector to the downside.
BIIB: 278.85 (+2.51), TSLA: 214.76 (+4.67), VRX: 102.53 (-16.08), KMB: 121.00 (+2.91), IBB: 305.37 (+0.91), SBUX: 61.22 (+0.69), YHOO: 31.85 (+0.73), CMG: 660.10 (-5.57), ABBV: 53.56 (-0.27), GOOGL: 682.32 (+10.52), AAPL: 115.10 (+1.34), KO: 43.64 (+1.45), AMZN: 566.90 (+11.13), MU: 16.70 (+0.27), PFE: 33.13 (-0.33), FCAU: 15.28 (+0.08), BA: 146.86 (+5.67), WDC: 72.40 (+0.96), CELG: 116.56 (+0.64), GILD: 102.42 (+0.69), LRCX: 72.26 (+1.47), GM: 35.47 (+0.05), MCD: 110.27 (+7.73), KLAC: 64.96 (+0.98), RACE: 56.31 (+1.31), SNDK: 76.90 (+0.12)
Stock Market News for October 21, 2015
Zacks Equity Research - Zacks Investment Research - Wed Oct 21, 9:10AM CDT
Benchmarks ended in the red on Tuesday, dragged down by declines in biotech and healthcare stocks
BIIB: 278.85 (+2.51), HOG: 47.64 (+0.61), IBM: 144.55 (+3.63), GILD: 102.42 (+0.69), UTX: 99.81 (+1.84), PFE: 33.13 (-0.33), MRK: 50.89 (+0.30), AMGN: 152.29 (+2.20), VZ: 45.81 (+0.95), REGN: 523.80 (+5.27), TRV: 112.39 (+1.69), CELG: 116.56 (+0.64)
Biogen (BIIB) Beats on 3Q Earnings & Revenues
Zacks Equity Research - Zacks Investment Research - Wed Oct 21, 7:54AM CDT
Biogen's (BIIB) third quarter results were well above expectations with revenues also topping estimates.
BIIB: 278.85 (+2.51)
Stock Futures Rise as Boeing, GM Beat Profit Forecasts
at The Street - Wed Oct 21, 7:25AM CDT
Stock futures are higher on Wednesday after better-than-expected earnings from General Motors and Boeing.
KO: 43.64 (+1.45), AMZN: 566.90 (+11.13), BIIB: 278.85 (+2.51), TSLA: 214.76 (+4.67), KMB: 121.00 (+2.91), FCAU: 15.28 (+0.08), BA: 146.86 (+5.67), SBUX: 61.22 (+0.69), YHOO: 31.85 (+0.73), CMG: 660.10 (-5.57), GM: 35.47 (+0.05), MCD: 110.27 (+7.73), GOOGL: 682.32 (+10.52), AAPL: 115.10 (+1.34)
